SARS-CoV-2 seroprevalence and neutralizing activity in donor and individual bloodstream
SARS-CoV-2 seroprevalence and neutralizing activity in donor and individual bloodstream. anti-RBD antibodies. Estimation of seroprevalence was performed with a weighted evaluation to reflect the united states population. We discovered an undiagnosed seropositivity price of 4.6% (95% CI: 2.6 C 6.5%). There is distinct local variability, with heightened seropositivity in places of early outbreaks. Subgroup evaluation…